Social Media Ideas for Ajax Therapeutics

Lilly’s Newly Acquired Drug Shows Promise as Next-Gen Blood Cancer Med

Eli Lilly presented encouraging Phase 1 results for AJ1-11095 at the European Hematology Association (EHA) annual meeting in Stockholm. The drug, a type II JAK2 inhibitor in develo...

Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.

ADC Therapeutics

ADC Therapeutics Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/adc-therapeutics.665008/...

Apogee Therapeutics: Targeting Atopic Dermatitis

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

Apogee eczema drugs gets Blackstone backing, heads to Phase 3

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

Novartis pays Antares $105M to illuminate undruggable cancer targets

Novartis is paying Antares Therapeutics $105 million upfront in a deal worth up to $1.9 billion to generate small molecules against historically undruggable oncology targets.

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Lilly scores early positive data for new JAK drug

Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Inc...

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Novartis to Acquire Myricx Bio for Up to $1.5B, Adding Cancer-Fighting ADC Payload Platform

Myricx Bio specializes in developing ADCs that use N-myristoyltransferase inhibitor (NMTi) payloads, an approach designed to deliver a differentiated cancer-killing payload directl...

Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup

Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue dru...

ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL - Slideshow

<![CDATA[Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Joh...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

<![CDATA[Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma ]]&g...

Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks - - If approv...

Novartis to acquire ADC developer in a deal worth up to $1.5B

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program

With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal stud...

A Spanish biotech banks $87M to make differentiated ADCs

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.